Mineralys Therapeutics Publishes Presentation on Lorundrostat in Chronic Kidney Disease
Bitget2026/10/23 19:31- Mineralys Therapeutics published a presentation on lorundrostat's blood pressure and albuminuria effects in chronic kidney disease in the Phase 3 Launch-HTN trial.
- Lorundrostat 50 mg daily produced statistically significant reductions in systolic blood pressure and urinary albumin-to-creatinine ratio in the CKD subgroup.
- The CKD subgroup included 192 participants with stages 1-3 disease; blood pressure responses did not differ significantly from participants without CKD.
- Across the overall trial, 50 mg lowered systolic blood pressure by 19.0 mmHg at 12 weeks, a placebo-adjusted reduction of 11.6 mmHg.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley comments on Coherent (COHR.US) Q1 financial report: not perfect but "good enough", the real highlight is the 20 billions USD long-term contract
Morgan Stanley has released its commentary on Coherent (COHR.US) following the company’s fiscal Q1 2027 earnings report, maintaining an "Equal-weight" rating and a target price of $325.
Nasdaq’s Staking Move: This Altcoin ETF News Stands Out from the Market! Here Are the Details
AI transformation potential does not equal investment returns! Plato Asset Management says the market is confusing two major logics, Nasdaq's plunge is just a "reality test"
David Allen, Head of Long/Short Strategies at Plato Investment Management, stated in an interview that Thursday's US stock market sell-off was the result of investors conflating the transformative potential of artificial intelligence (AI) with the actual investment return argument.
Chainalysis says breach exposed password hashes and live tokens
Crypto prices
More
